Skip to main content
Top
Published in: Clinical Rheumatology 11/2017

01-11-2017 | Original Article

Association between primary biliary cholangitis and osteoporosis: meta-analysis

Authors: Junyu Fan, Qian Wang, Lingyun Sun

Published in: Clinical Rheumatology | Issue 11/2017

Login to get access

Abstract

The relationship between primary biliary cholangitis (PBC, previously termed primary biliary cirrhosis) and risks of osteoporosis remains controversial. This meta-analysis was designed to comprehensively analyze the association between PBC and osteoporosis. We conducted a systematic literature search of the PubMed, EMBASE, and Web of Science. Either fixed or random effects models were applied to assess bone mineral density (BMD), osteoporosis rates, and fractures in PBC patients and normal controls. A total of eight studies were included (including 1643 PBC patients and 10,921 controls). PBC patients had a relative risk (RR) of 2.79 (95% CI 1.26 to 6.16) for the development of osteoporosis, lower lumbar spine BMD (95% CI − 0.13 to − 0.04, P = 0.0002), hip BMD (95% CI − 0.13 to − 0.03, P = 0.002), and lumbar spine t score (95% CI − 1.69 to − 1.02, P < 0.00001) than controls. Moreover, PBC patients had an OR of 1.86 (95%CI 1.54 to 2.24, P < 0.00001) for the development of fractures. Collectively, this meta-analysis indicates that PBC patients were more likely to suffer from osteoporosis. Given the limited literature available, better designed and larger scale primary studies will be required to confirm our conclusion.
Appendix
Available only for authorised users
Literature
1.
go back to reference Beuers U, Gershwin ME, Gish RG et al (2015) Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’. Gut 64:1671–1672CrossRefPubMed Beuers U, Gershwin ME, Gish RG et al (2015) Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’. Gut 64:1671–1672CrossRefPubMed
2.
go back to reference Hirschfield GM, Gershwin ME (2013) The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 8:303–330CrossRefPubMed Hirschfield GM, Gershwin ME (2013) The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 8:303–330CrossRefPubMed
4.
go back to reference Carbone M, Mells GF, Pells G et al (2013) Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 144:560–569 e567 quiz e513-564CrossRefPubMed Carbone M, Mells GF, Pells G et al (2013) Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 144:560–569 e567 quiz e513-564CrossRefPubMed
5.
go back to reference Raszeja-Wyszomirska J, Miazgowski T (2014) Osteoporosis in primary biliary cirrhosis of the liver. Prz Gastroenterol 9:82–87PubMedPubMedCentral Raszeja-Wyszomirska J, Miazgowski T (2014) Osteoporosis in primary biliary cirrhosis of the liver. Prz Gastroenterol 9:82–87PubMedPubMedCentral
6.
go back to reference Kanis JA (2008) Assessment of osteoporosis at the primary health care level. Technical Report WHO Collaborating Centre for Metabolic Bone Diseases University of Sheffield, UK Kanis JA (2008) Assessment of osteoporosis at the primary health care level. Technical Report WHO Collaborating Centre for Metabolic Bone Diseases University of Sheffield, UK
7.
go back to reference Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis F (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381CrossRefPubMedPubMedCentral Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis F (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381CrossRefPubMedPubMedCentral
8.
go back to reference van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787CrossRefPubMed van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787CrossRefPubMed
9.
go back to reference De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214CrossRefPubMed De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214CrossRefPubMed
10.
go back to reference Leidig-Bruckner G, Grobholz S, Bruckner T, Scheidt-Nave C, Nawroth P, Schneider JG (2014) Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Disord 14:33CrossRefPubMedPubMedCentral Leidig-Bruckner G, Grobholz S, Bruckner T, Scheidt-Nave C, Nawroth P, Schneider JG (2014) Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Disord 14:33CrossRefPubMedPubMedCentral
11.
go back to reference van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK (2003) Inflammatory bowel disease and the risk of fracture. Gastroenterology 125:1591–1597CrossRefPubMed van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK (2003) Inflammatory bowel disease and the risk of fracture. Gastroenterology 125:1591–1597CrossRefPubMed
12.
go back to reference Laakso S, Valta H, Verkasalo M, Toiviainen-Salo S, Makitie O (2014) Compromised peak bone mass in patients with inflammatory bowel disease—a prospective study. J Pediatr 164(1436–1443):e1431 Laakso S, Valta H, Verkasalo M, Toiviainen-Salo S, Makitie O (2014) Compromised peak bone mass in patients with inflammatory bowel disease—a prospective study. J Pediatr 164(1436–1443):e1431
13.
go back to reference Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW, Cedel SL, Riggs BL, Krom RA (1991) Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 14:296–300CrossRefPubMed Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW, Cedel SL, Riggs BL, Krom RA (1991) Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 14:296–300CrossRefPubMed
14.
go back to reference Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD (2001) Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 35:316–323CrossRefPubMed Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD (2001) Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 35:316–323CrossRefPubMed
15.
go back to reference Guanabens N, Pares A, Ros I, Caballeria L, Pons F, Vidal S, Monegal A, Peris P, Rodes J (2005) Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 42:573–577CrossRefPubMed Guanabens N, Pares A, Ros I, Caballeria L, Pons F, Vidal S, Monegal A, Peris P, Rodes J (2005) Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 42:573–577CrossRefPubMed
16.
go back to reference Floreani A, Mega A, Camozzi V, Baldo V, Plebani M, Burra P, Luisetto G (2005) Is osteoporosis a peculiar association with primary biliary cirrhosis? World J Gastroenterol 11:5347–5350CrossRefPubMedPubMedCentral Floreani A, Mega A, Camozzi V, Baldo V, Plebani M, Burra P, Luisetto G (2005) Is osteoporosis a peculiar association with primary biliary cirrhosis? World J Gastroenterol 11:5347–5350CrossRefPubMedPubMedCentral
17.
go back to reference Wariaghli G, Mounach A, Achemlal L, Benbaghdadi I, Aouragh A, Bezza A, El Maghraoui A (2010) Osteoporosis in chronic liver disease: a case-control study. Rheumatol Int 30:893–899CrossRefPubMed Wariaghli G, Mounach A, Achemlal L, Benbaghdadi I, Aouragh A, Bezza A, El Maghraoui A (2010) Osteoporosis in chronic liver disease: a case-control study. Rheumatol Int 30:893–899CrossRefPubMed
18.
19.
go back to reference Solerio E, Isaia G, Innarella R, Di Stefano M, Farina M, Borghesio E, Framarin L, Rizzetto M, Rosina F (2003) Osteoporosis: still a typical complication of primary biliary cirrhosis? Dig Liver Dis 35:339–346CrossRefPubMed Solerio E, Isaia G, Innarella R, Di Stefano M, Farina M, Borghesio E, Framarin L, Rizzetto M, Rosina F (2003) Osteoporosis: still a typical complication of primary biliary cirrhosis? Dig Liver Dis 35:339–346CrossRefPubMed
20.
go back to reference Benetti A, Crosignani A, Varenna M, Giussani CS, Allocca M, Zuin M, Podda M, Battezzati PM (2008) Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study. J Clin Gastroenterol 42:306–311PubMed Benetti A, Crosignani A, Varenna M, Giussani CS, Allocca M, Zuin M, Podda M, Battezzati PM (2008) Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study. J Clin Gastroenterol 42:306–311PubMed
21.
go back to reference Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed
23.
go back to reference Boulton-Jones JR, Fenn RM, West J, Logan RF, Ryder SD (2004) Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls. Aliment Pharmacol Ther 20:551–557CrossRefPubMed Boulton-Jones JR, Fenn RM, West J, Logan RF, Ryder SD (2004) Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls. Aliment Pharmacol Ther 20:551–557CrossRefPubMed
24.
go back to reference Solaymani-Dodaran M, Card TR, Aithal GP, West J (2006) Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 131:1752–1757CrossRefPubMed Solaymani-Dodaran M, Card TR, Aithal GP, West J (2006) Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 131:1752–1757CrossRefPubMed
25.
go back to reference Handzlik-Orlik G, Holecki M, Wilczynski K, Dulawa J (2016) Osteoporosis in liver disease: pathogenesis and management. Ther Adv Endocrinol Metab 7:128–135CrossRefPubMedPubMedCentral Handzlik-Orlik G, Holecki M, Wilczynski K, Dulawa J (2016) Osteoporosis in liver disease: pathogenesis and management. Ther Adv Endocrinol Metab 7:128–135CrossRefPubMedPubMedCentral
26.
go back to reference Gatta A, Verardo A, Di Pascoli M, Giannini S, Bolognesi M (2014) Hepatic osteodystrophy. Clin Cases Miner Bone Metab 11:185–191PubMedPubMedCentral Gatta A, Verardo A, Di Pascoli M, Giannini S, Bolognesi M (2014) Hepatic osteodystrophy. Clin Cases Miner Bone Metab 11:185–191PubMedPubMedCentral
27.
go back to reference Nakchbandi IA, van der Merwe SW (2009) Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol 6:660–670CrossRefPubMed Nakchbandi IA, van der Merwe SW (2009) Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol 6:660–670CrossRefPubMed
28.
go back to reference Khanh vinh LN, Nguyen LT (2013) The role of vitamin d in primary biliary cirrhosis: possible genetic and cell signaling mechanisms. Gastroenterol Res Pract 2013:602321 Khanh vinh LN, Nguyen LT (2013) The role of vitamin d in primary biliary cirrhosis: possible genetic and cell signaling mechanisms. Gastroenterol Res Pract 2013:602321
29.
go back to reference Vogel A, Strassburg CP, Manns MP (2002) Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 35:126–131CrossRefPubMed Vogel A, Strassburg CP, Manns MP (2002) Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 35:126–131CrossRefPubMed
30.
go back to reference Guo GY, Shi YQ, Wang L et al (2015) Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis. Aliment Pharmacol Ther 42:221–230CrossRefPubMed Guo GY, Shi YQ, Wang L et al (2015) Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis. Aliment Pharmacol Ther 42:221–230CrossRefPubMed
31.
go back to reference Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Muhllechner P, Habior A, Graziadei I, Vogel W, Tilg H (2005) The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 43:973–983CrossRefPubMed Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Muhllechner P, Habior A, Graziadei I, Vogel W, Tilg H (2005) The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 43:973–983CrossRefPubMed
32.
go back to reference Cemborain A, Castilla-Cortazar I, Garcia M, Muguerza B, Delgado G, Diaz-Sanchez M, Picardi A (2000) Effects of IGF-I treatment on osteopenia in rats with advanced liver cirrhosis. J Physiol Biochem 56:91–99CrossRefPubMed Cemborain A, Castilla-Cortazar I, Garcia M, Muguerza B, Delgado G, Diaz-Sanchez M, Picardi A (2000) Effects of IGF-I treatment on osteopenia in rats with advanced liver cirrhosis. J Physiol Biochem 56:91–99CrossRefPubMed
33.
go back to reference Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL (1995) Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 95:2581–2586CrossRefPubMedPubMedCentral Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL (1995) Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 95:2581–2586CrossRefPubMedPubMedCentral
34.
go back to reference Ruiz-Gaspa S, Guanabens N, Enjuanes A et al (2010) Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Investig 40:25–34CrossRef Ruiz-Gaspa S, Guanabens N, Enjuanes A et al (2010) Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Investig 40:25–34CrossRef
35.
go back to reference Ruiz-Gaspà S, Martinez-Ferrer A, Enjuanes A, Peris P, Osaba MJMD, Alvarez L, Monegal A, Combalia A, Parés A, Guañabens N (2010) High bilirubin reduces cell survival and differentiation of primary human osteoblasts. Is this effect applicable to the serum of chronic cholestatic patients? Bone 47:S214–S215CrossRef Ruiz-Gaspà S, Martinez-Ferrer A, Enjuanes A, Peris P, Osaba MJMD, Alvarez L, Monegal A, Combalia A, Parés A, Guañabens N (2010) High bilirubin reduces cell survival and differentiation of primary human osteoblasts. Is this effect applicable to the serum of chronic cholestatic patients? Bone 47:S214–S215CrossRef
36.
go back to reference Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770CrossRefPubMed Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770CrossRefPubMed
37.
go back to reference Ormarsdottir S, Ljunggren O, Mallmin H, Olofsson H, Blum WF, Loof L (2001) Inverse relationship between circulating levels of leptin and bone mineral density in chronic liver disease. J Gastroenterol Hepatol 16:1409–1414CrossRefPubMed Ormarsdottir S, Ljunggren O, Mallmin H, Olofsson H, Blum WF, Loof L (2001) Inverse relationship between circulating levels of leptin and bone mineral density in chronic liver disease. J Gastroenterol Hepatol 16:1409–1414CrossRefPubMed
38.
go back to reference Szalay F, Folhoffer A, Horvath A et al (2005) Serum leptin, soluble leptin receptor, free leptin index and bone mineral density in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 17:923–928CrossRefPubMed Szalay F, Folhoffer A, Horvath A et al (2005) Serum leptin, soluble leptin receptor, free leptin index and bone mineral density in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 17:923–928CrossRefPubMed
39.
go back to reference Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, Lindor KD (2005) Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 42:762–771CrossRefPubMed Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, Lindor KD (2005) Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 42:762–771CrossRefPubMed
40.
go back to reference Guanabens N, Monegal A, Cerda D, Muxi A, Gifre L, Peris P, Pares A (2013) Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology 58:2070–2078CrossRefPubMed Guanabens N, Monegal A, Cerda D, Muxi A, Gifre L, Peris P, Pares A (2013) Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology 58:2070–2078CrossRefPubMed
Metadata
Title
Association between primary biliary cholangitis and osteoporosis: meta-analysis
Authors
Junyu Fan
Qian Wang
Lingyun Sun
Publication date
01-11-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 11/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3844-x

Other articles of this Issue 11/2017

Clinical Rheumatology 11/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.